Drug Profile
Research programme: Alzheimer's disease therapies - Neurologix
Latest Information Update: 24 Aug 2009
Price :
$50
*
At a glance
- Originator Neurologix
- Class Gene therapies
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 18 May 2005 Preclinical trials in Alzheimer's disease in USA (unspecified route)